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Preeclampsia and the C282Y
Mutation in the Hemochromatosis
(HFE) Gene
To the Editor:
The hemochromatosis (HFE) gene
encodes the HFE protein, a trans-
membrane glycoprotein that is im-
plicated in the modulation of iron
uptake from the diet (1 ). The C282Y
mutation in this gene is known to be
associated with moderately in-
creased serum iron indices. Recently,
several studies have described an as-
sociation between increased mater-
nal iron status and an unfavorable
pregnancy outcome (2, 3). Pre-
eclampsia is one of the most common
pregnancy-related syndromes as
well as a major cause of fetal and
maternal morbidity and mortality.
Preeclampsia is defined by de novo
hypertension and proteinuria in
pregnancy. The etiology of pre-
eclampsia is complex and not fully
understood, but abnormal placenta-
tion and endothelial dysfunction
may play an important role in its
pathogenesis. Abnormal placenta-
tion may lead to a malperfused pla-
centa with release of toxic iron
through hemoglobin or heme, which
finally may contribute to generalized
endothelial dysfunction (2 ). In the
present study, we analyzed the asso-
ciation between the C282Y allele and
the presence of preeclampsia in a
case–control study described previ-
ously (4 ). The analysis was restricted
to those patients and their controls
who fulfilled recent criteria for pre-
eclampsia (157 women in each
group).
The HFE C282Y genotype was de-
termined by an automated method
using minor-groove-binding DNA
oligonucleotides (MGB probes) as
described previously (5 ). The pres-
ence of a C282Y allele was confirmed
by conventional PCR with restriction
fragment length polymorphism anal-
ysis.
A Fisher exact test with a 0.050
one-sided significance level showed
90% power to detect the difference
between a C282Y allele frequency
of 10% (estimated population fre-
quency) and a case frequency of
22.5% (odds ratio  2.8) when the
sample size in each group was 157.
The observed frequency for the
HFE C282Y allele was similar for
women with preeclampsia and con-
trols (0.070). In addition, there was
no significant difference between
cases and controls in the frequency of
the three genotypes [wild type (wt)/
wt, wt/C282Y, and C282Y/C282Y]
or the presence of the C282Y allele
(wt/C282Y and C282Y/C282Y; Table
1). Furthermore, we found that ad-
justment for clinical indices previ-
ously positively (familial hyperten-
sion and body mass index) and
negatively (smoking) associated with
preeclampsia in a logistic model had
no significant effect on the distribu-
tion of the various C282Y genotypes
among women who developed pre-
eclampsia and controls.
The finding of no differences in the
C282Y allele distribution or the fre-
quency of the C282Y allele between
women with pregnancies compli-
cated by preeclampsia and controls
with uncomplicated pregnancies
suggests that the C282Y polymor-
phism is not predominantly involved
in the development of endothelial
cell dysfunction as a result of in-
creased iron caused by this mutation
in women with preeclampsia.
In the total group of cases and
controls we found a high frequency
(1 of 63) of women who were ho-
mozygous for the C282Y allele,
whereas 1 in 9 were heterozygous for
this allele. The proportion of preg-
nant women in the present study
who had the C282Y/C282Y genotype
(1.6%), however, did not differ sig-
nificantly from the frequency of 0.3–
0.5% reported previously for individ-
uals of Northern European descent
(1 ).
In conclusion, our data do not sup-
port the hypothesis that the C282Y
allele of the hemochromatosis (HFE)
gene is a clinically important marker
of an increased risk for the develop-
ment of preeclampsia.
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Table 1. Genotype frequencies in women with preeclampsia and control women.
Genotype
Women with
preeclampsia
(n  157)
Controls
(n  157) Odds ratioa
(95% confidence
interval)n % n %
wt/wt 137 87.2 138 87.9 1.0
wt/C282Y 18 11.5 16 10.2 1.13 (0.56–4.27)
C282Y/C282Y 2 1.3 3 1.9 0.67 (0.11–3.12)
wt/C282Y or C282Y/C282Y 20 12.8 19 12.1 1.06 (0.54–4.08)
fC282Yb 0.067 0.070
a Odds ratios were determined by multiple logistic regression analysis.
b Frequency of the C282Y allele. For women with preeclampsia and controls, the observed vs expected
allele frequencies are 1.27% (95% confidence interval, 0.15–4.5%) and 1.91% (0.4–5.5%), respectively.
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Influence of Preanalytical Factors on
the Immulite Intact Parathyroid
Hormone Assay
To the Editor:
Preanalytical factors that affect para-
thyroid hormone (PTH) concentra-
tions are not well defined. Measured
PTH concentrations in EDTA plasma
may (1, 2) or may not (3 ) differ from
those in serum. PTH has been re-
ported variously to be stable for
hours to days (1–6). In addition, dif-
ferent PTH assays cross-react to var-
ious extents with biologically inac-
tive, N-terminally truncated PTH
molecules (7 ) that may have differ-
ent stabilities. The specificity of a
given immunometric assay depends
on the binding sites of the anti-PTH
antibodies used. So-called “intact”
PTH (iPTH) assays show cross-reac-
tivity with peptides lacking N-termi-
nal amino acids. Assays measuring
only PTH with intact NH2 termini
are named CAPTM; whole PTH, 3rd
generation; or bioactive PTH assays
(7 ).
In 2001, DPC introduced a refor-
mulated iPTH sandwich assay (start-
ing with lot no. 106) in which the
polyclonal tracer antibody had been
replaced by a monoclonal antibody
raised against an epitope within the
first 34 amino acids of PTH. With this
new method, reference intervals and,
in particular, PTH concentrations
measured in serum samples of dial-
ysis patients are lower (data not
shown). In March 2003, DPC re-
ported underrecovery of PTH with
this method (8 ), and a new lot of raw
materials was introduced, starting
with assay lot no. 112. The calibra-
tion for the Immulite analyzer was
adjusted at assay lot no. 113 (8 ).
Shortly before this, we had found
that PTH concentrations in EDTA
plasma measured with lot no. 109
apparently increased with time (data
not shown), whereas a previous re-
port (1 ) indicated that PTH as mea-
sured by this method was stable in
EDTA plasma (1 ). The changes in the
PTH assay and the conflicting results
on PTH stability in EDTA samples
led us to investigate with the newer
monoclonal/polyclonal iPTH assay
both PTH reference intervals and sta-
bility as well as agreement between
the PTH measurements on the Im-
mulite and Immulite 2000 analyzers.
Reference intervals were estimated
by the nonparametric method in An-
alyze-It for Microsoft Excel, based on
results for material from nonpreg-
nant volunteers from the outpatient
clinic (age range, 20–65 years). Indi-
viduals suffering from renal failure
or taking vitamin and/or mineral
supplements were not included in
the study. All samples were obtained
between 0900 and 1300. Almost all
volunteers (98%) were Caucasians;
61% were female, and 39% were
male. Blood was collected into two
dipotassium EDTA VacutainerTM
tubes (plastic; BD) and into a serum
tube with clot activator and SSTIITM
gel. Heparin plasma was not in-
cluded in the study because mea-
surement of PTH in heparin plasma
frequently led to inexplicable outliers
(data not shown). After venipunc-
ture, one EDTA tube was immedi-
ately put into melting ice (EDTAice),
the other EDTA and the serum tube
were kept at room temperature. Se-
rum tubes were allowed to clot be-
fore centrifugation. EDTAice plasma
was centrifuged at 4 °C. PTH was
assayed on an Immulite 2000 (assay
lot no. 112) and an Immulite (assay
lot no. 113) analyzer within 2.5 h of
venipuncture, according to the man-
ufacturer’s protocols.
Of the 137 volunteers, 9 had PTH
concentrations more than 1.5 inter-
quartile ranges from the first quartile
above the median and were investi-
gated as possible outliers. All nine
samples had pathologically low cal-
cium concentrations or increased
plasma phosphate or creatinine con-
centrations and thus were excluded
from the reference interval study. To
assess the stability of PTH, we re-
tested samples that had been stored
as serum and plasma at 4 °C on the
Immulite 2000 48 h after the initial
measurements.
PTH measured in serum was
lower than in EDTA or EDTAice
plasma (P0.0001, Wilcoxon signed-
ranks test). For comparison Table 1
also contains results from a similar
reference interval study we had con-
ducted previously with lot no. 109.
The PTH concentrations found with
lot no. 112 on the Immulite 2000 were
slightly higher than in the reference
interval study with lot no. 109. When
we used the same samples, the refer-
ence intervals determined with the
Immulite were higher than those de-
termined with the Immulite 2000.
Table 1. Median PTH concentrations and estimated nonparametric 95%
reference intervals obtained on Immulite and Immulite 2000 analyzers.
Analyzer
PTH assay
lot no.a
No. of
samples Material
Median,
pmol/L
Reference interval,
pmol/L
Immulite 113 124 Serum 3.5b 1.4–6.3
124 EDTA 4.6 2.0–8.3
124 EDTAice 3.9 1.5–7.8
Immulite 2000 112 128 Serum 2.8b 1.2–5.2
128 EDTA 3.8 1.6–7.0
128 EDTAice 3.3 1.4–6.1
Immulite 2000 109 134 Serum 2.1b 0.7–4.9
121 EDTA 2.7 0.9–5.8
135 EDTAice 2.4 0.6–5.2
a Lot nos. 112 and 113 are “improved” lots of the monoclonal/polyclonal assay reagent sets, whereas lot
no. 109 is from the original monoclonal/polyclonal assay reagent set.
b P 0.0001 vs corresponding EDTA or EDTAice samples (Wilcoxon signed-ranks test).
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